The results fell short of Wall Street expectations. The average estimate of eight analysts surveyed by Zacks Investment Research was for earnings of $1.14 per share.

BATON ROUGE, La., Nov. 06, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED) today reported its financial results for the three and nine-month periods ended September 30, 2024. Net service ...

Leaders at UnitedHealth Group and Amedisys are set to meet with the Department of Justice (DOJ) this week in hopes of avoiding a potential attempt to block their $3.3 billion merger deal ...

Amedisys , which agreed to a $101 a share sale to UnitedHealth in late June of last year, is waiting for the Dept. of Justice ...

UnitedHealth Group Inc. and Amedisys Inc. representatives are slated to meet with top Justice Department antitrust enforcers ...

BATON ROUGE, La., Sept. 25, 2024 (GLOBE NEWSWIRE) -- Amedisys, Inc. (NASDAQ: AMED), a leading provider of home health, hospice and high-acuity care in the home, has 92 home health and hospice care ...

A stock is considered to be oversold if the RSI reading falls below 30. In trading on Thursday, shares of Amedisys, Inc. (Symbol: AMED) entered into oversold territory, hitting an RSI reading of ...

Amedisys (NASDAQ:AMED) dropped 5.1% amid a report that a potential divestiture buyer in its planned sale to UnitedHealth ...

The latest update is out from Amedisys ( (AMED) ).

UnitedHealth Group Inc. and Amedisys Inc. representatives are slated to meet with top Justice Department antitrust enforcers next week in a last-ditch effort to persuade the agency not to ...

Amedisys, Inc. is being acquired by UnitedHealth for $3.3 billion, pending DOJ approval, with the stock currently trading below the offer price. The DOJ is scrutinizing the merger due to concerns ...

AMED Or CHE: Which Is The Better Value Stock Right Now? Investors interested in Medical - Outpatient and Home Healthcare stocks are likely familiar with Amedisys (NASDAQ: AMED) and Chemed (NYSE: CHE).